Company intelligence / Profile preview

POLYGON Therapeutics

Paris, Île-de-France, Francepolygon.care ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Polygon’s lead candidate, PLG-101, has met all pre-clinical milestones and is advancing to clinical development with a first-in-human Phase 1 trial scheduled for late 2025. The company has demonstrated promising results in both in vitro and in vivo studies and is finalizing manufacturing scale-up for clinical trials. Seed financing of $7.5M was recently completed to support this transition.[6]

Therapeutic areas: Cardiovascular
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

PLG-101

Preclinical

Beyond the preview

Go deeper on POLYGON Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on POLYGON Therapeutics.

Explore the full profile